Fundraising Fox
Vitae Industries
Techstars '17Providence, US · Founded 2014 · Delaware corporation · 3 employees on LinkedIn · 8 known investors
Find your way into Vitae Industries
Each arrow is one introduction. Sign up to fill in the first one.
Ask Sid Kalla to introduce you to Jeanine Sinanan-Singh
You →Sid · together at Techstars New York City Accelerator 2017 →Jeanine
Ask Jamie Chen to introduce you to Anthony Marsella
You →Jamie · together at Techstars New York City Accelerator 2017 →Anthony
Sign up to find every way you can get introduced to Vitae Industries
- Your email: who you already know at Vitae Industries, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Vitae Industries team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
BetteRx (formerly Vitae Industries) builds the AutoCompounder, an automated dosage-making system with a vetted compound formulary that helps 503A compounding pharmacists produce personalized medications more consistently and in line with FDA regulations. It serves compounding pharmacies in the US, with installations across the country.
Also known as BetteRx · BetteRx Compounding Inc. · Vitae Industries
Founders & leadership
Vitae Industries was founded in 2014 by Jeanine Sinanan-Singh, Daniel DeCiccio, and Anthony Marsella.
Investors · 8
How we know: Compound's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Slater Technology Fund's portfolio page · funding news · pbn.com · Not right? Tell us
How we know: Social Starts's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: the Techstars portfolio · pbn.com · Not right? Tell us
How we know: pbn.com · Not right? Tell us
How we know: pbn.com · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 3 rounds · 2016–2017
▶$2.3MraisedAug 2017 · 12 investors · BiotechnologyRule 506(b)
- Jeanine Sinanan-SinghExecutive Officer, Director
- Daniel DeCiccioExecutive Officer, Director
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Minimum investment
- $25.5K
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$200KraisedJan 2017 · 3 investors · BiotechnologyRule 506(b)
- Jeanine Sinanan-SinghExecutive Officer, Director
- Daniel DeCiccioExecutive Officer, Director
- Offering amount
- $750K
- Amount sold
- $200K
- Minimum investment
- $25K
- First sale
- Jan 2017
- Incorporated
- Corporation, Rhode Island, 2015
- Federal exemptions
- 06b
▶$20KraisedDec 2016 · 1 investors · BiotechnologyRule 506(b)
- Jeanine Sinanan-SinghExecutive Officer, Director
- Daniel DeCiccioExecutive Officer, Director
- Offering amount
- $20K
- Amount sold
- $20K
- First sale
- Nov 2016
- Incorporated
- Corporation, Rhode Island, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026BetteRx Compounding Inc., formerly Vitae Industries, develops automation technology for pharmacy compounding. Its AutoCompounder system produces personalized medication doses through a three-step workflow: the pharmacist mixes the active pharmaceutical ingredient (API) with dosage-form-specific inactive ingredients according to the company's vetted formulas, fills a proprietary cartridge with the compound and clips it into the AutoCompounder, then enters the drug, strength(s) and quantity for the machine to dispense doses unattended.
The company positions its system as aligned with FDA regulations and the requirements of the Drug Quality and Security Act, legislation enacted following the New England Compounding Center meningitis outbreak. Its stated goal is to make personalized, compounded medication safer and as scalable and accessible as generic drugs by equipping 503A compounding pharmacists with automated dispensing technology.
Business model
The company supplies compounding pharmacies with the AutoCompounder system, proprietary cartridges and an associated vetted compound formulary.
Traction
The company reports its system in more than 28 pharmacy installations nationwide, a compound formulary of over 300 APIs, and more than 500,000 doses dispensed by the AutoCompounder.
Latest developments
BetteRx Compounding Inc. now operates the business under the BetteRx name, stating on its website that it acquired Vitae Industries' technology, and reports over 28 pharmacy installations and more than 500,000 doses dispensed.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
The company describes itself as focused on automating personalized compounded medication production for 503A pharmacies, with its system installed in over 28 pharmacies nationwide.
Technology
The core product is the AutoCompounder, a cartridge-based automated dosage-dispensing machine paired with a compound formulary. The pharmacist prepares a compound from an API and dosage-form-specific inactive ingredients using the company's vetted formulas, loads it into a cartridge, and enters the drug, strengths and quantity; the system then dispenses the doses. The formulary covers more than 300 compound APIs.
Go-to-market
503A compounding pharmacies in the United States and the compounding pharmacists working in them.
Geography
United States; the company describes installations in pharmacies nationwide.
History
The business operated as Vitae Industries before becoming BetteRx Compounding Inc.; the company's site states that BetteRx acquired Vitae Industries' technology.
Compiled by commissioned research from 11 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Related companies · 2
Companies working in the same space as Vitae Industries.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $149.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Timeline · 1
launches, deals, and filingsThe company's website states that BetteRx acquired Vitae Industries' technology and that BetteRx Compounding Inc. was formerly Vitae Industries.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structure▸Research sources · 11
primary sources listed
- Vitae Industriessimplybetterx.com · web
- Vitaevitaeindustries.com · web
11 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Vitae Industries do?
- BetteRx, formerly Vitae Industries, makes the AutoCompounder, an automated dosage-making system for 503A compounding pharmacies.
- Who founded Vitae Industries?
- Vitae Industries was founded by Jeanine Sinanan-Singh, Daniel DeCiccio, Anthony Marsella in 2014.
- Who are Vitae Industries's investors?
- Vitae Industries's investors include Compound, Slater Technology Fund, Social Starts, Techstars, BoxGroup, Founder Collective, Lerer Hippeau.
- How much funding has Vitae Industries raised?
- Vitae Industries has disclosed $2.5M raised across 3 rounds.
- Where is Vitae Industries headquartered?
- Vitae Industries is headquartered in Providence, US.